Brand | Abnova |
Product type | Primary antibodies |
Reactivity | Human,Mouse |
Host species | Rabbit |
Applications | IP,ELISA,IHC,WB-Ce |
Brand: | Abnova |
Reference: | PAB12618 |
Product name: | CSF1R (phospho Y723) polyclonal antibody |
Product description: | Rabbit polyclonal antibody raised against synthetic phosphopeptide of CSF1R. |
Gene id: | 1436 |
Gene name: | CSF1R |
Gene alias: | C-FMS|CD115|CSFR|FIM2|FMS |
Gene description: | colony stimulating factor 1 receptor |
Immunogen: | Synthetic phosphopeptide corresponding to residues surrounding Y723 of human CSF1R. |
Immunogen sequence/protein sequence: | DTYVEM |
Form: | Liquid |
Recommend dilutions: | Western Blot (0.1-1 ug/mL) ELISA (0.01-0.1 ug/mL) Immunoprecipitation (2-5 ug/mL) Immunohistochemistry (2-5 ug/mL) The optimal working dilution should be determined by the end user. |
Storage buffer: | In TBS, pH 7.2 (BSA, 10% Proclin300) |
Storage instruction: | Store at 4°C for three month. For long term storage store at -20°C to -80°C. Aliquot to avoid repeated freezing and thawing. |
Quality control testing: | Antibody Reactive Against Synthetic Peptide. |
Product type: | Primary antibodies |
Host species: | Rabbit |
Antigen species / target species: | Human |
Specificity: | This antibody recognizes ~150 KDa of human CSF1R at a phosphorylation site of Tyrosine 723. It does not recognize non-phosphorylated peptides. |
Reactivity: | Human,Mouse |
Application image: | ![]() |
Application image note: | The whole cell lysate derived from m-CSF stimulated LNCaP was immunoblotted by CSF1R (phospho Y723) polyclonal antibody (Cat # PAB12618) at 1 : 500. A major immune-reactive band is observed around ~ 150 KDa (Lane 1). This band is blocked by pre-incubation of immunizing peptide (Lane 2). |
Applications: | IP,ELISA,IHC,WB-Ce |
Shipping condition: | Dry Ice |
Publications: | The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma.Toy EP, Chambers JT, Kacinski BM, Flick MB, Chambers SK. Gynecol Oncol. 2001 Feb;80(2):194-200. |